Skip to main content
Local News

CQDM and Brain Canada Inject $1 M in Top BC Biotech Firm Abcellera to Advance Discovery Platform for Next-Generation Antibody Therapeutics

By January 25, 2018No Comments

CQDM and Brain Canada are proud to announce the non-dilutive funding of $1 M to AbCellera and the University of British Columbia. AbCellera will also contribute $450,000 to the project, which will expand and apply its state-of-the-art microfluidic antibody discovery platform for discovery of function-modifying antibodies against GPCR targets.

The CQDM support was made possible by the financial contributions of five of its industrial members, including GSK, Janssen Pharmaceutical Companies of Johnson & Johnson, Merck, Pfizer, and Sanofi. These contributions underscore their commitment to driving innovation that can expand the accessible target space of antibody-based therapeutics, the fastest growing class of drugs. Brain Canada’s contribution was made through the Canada Brain Research Fund, with financial support from Health Canada.

“This project is particularly important for CQDM.It highlights our ability to support top biotech companies across Canada, and our focus on game-changing and transformative platform technologies in areas that are key to many pharmaceutical development programs”, said Diane Gosselin, President and CEO of CQDM.

“Collaboration across sectors and disciplines is central to Brain Canada’s vision, and is key to accelerating the pace of discovery. We are pleased to support this research project aiming to develop novel platforms for next-generation biological therapeutics”, said Inez Jabalpurwala, President and CEO of Brain Canada.